- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06090422
Cetamina para depressão combinada e transtorno por uso de álcool (KeDA)
Cetamina para depressão combinada e transtorno por uso de álcool: um ensaio cego randomizado ativo controlado por placebo (o ensaio KeDA)
The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Depression and alcohol use disorder (AUD) often coexist and can create significant challenges for individuals seeking effective treatment. Traditional treatment approaches have shown limited success in addressing both conditions simultaneously. Ketamine has shown to have promising rapid antidepressant effects and a possible role in the treatment of substance use disorders. By targeting both depression and AUD simultaneously, ketamine has the potential to offer dual benefits, improving depressive symptoms while addressing alcohol cravings or consumption. Furthermore, rapid relief from depressive symptoms may enhance motivation for recovery, reduce the risk of relapse, and improve overall treatment engagement and outcomes. Although ketamine is generally considered safe when administered under medical supervision, the safety profile in individuals with comorbid depression and AUD needs further investigation. The overall objective of this study is to examine the safety and efficacy of ketamine on adults with depression and AUD that are admitted for standard inpatient addiction therapy.
The study will only include adults with at least moderate depression and alcohol use disorder as their primary substance use disorder that are admitted for inpatient addiction therapy. Participants that are unable to give informed consent or have contraindication(s) for ketamine will be excluded.
After screening and enrollment, participants will undergo baseline assessments with measures on depression (using Montgomery-Åsberg Depression Rating Scale (MADRS) and Beck Depression Inventory-II (BDI-II)), alcohol use (using Timeline Follow-Back method (TLFB)), alcohol craving (using Short version of Alcohol Craving Questionnaire (ACQ-Short) and Penn Alcohol Craving Scale (PACS)) and neurocognitive function (using Cambridge Neuropsychological Test Automated Battery (CANTAB)). Participants will then be randomized to intervention group or control group. The intervention group will receive ketamine as four single doses, given biweekly for two weeks. The control group will receive midazolam as active placebo. Participants will undergo several follow-up assessments after treatment (1-2 day(s), 1 week, 2 weeks and 4 weeks after treatment). Final follow-up assessment will be 6 months after baseline.
By using open questions and specific instruments for assessing adverse effects associated with ketamine (using modified version of Ketamine Side Effect Tool (mKSET)), the trial will assess the frequency, severity and duration of any adverse events and severe adverse events. All adverse events will be evaluated with regards to its causal relationship to ketamine. In addition, physician-assessed and patient-assessed tolerability will be registered. Changes in neurocognitive function from baseline will be assessed after treatment.
Changes in depression will be measured several times using rater-blinded MADRS-assessment and self-report instrument (BDI-II). Measures of alcohol use (TLFB), alcohol craving (ACQ-short and PACS), relapse risk and time until relapse will used as measures on alcohol use disorder following treatment. Several exploratory objectives will be examined, including changes in alcohol dependence severity (using Severity of Alcohol Dependence Questionnaire (SADQ)), changes in quality of life (using World Health Organizations brief quality of life questionnaire (WHOQOL-BREF)), changes in self-reported treatment effectiveness (using Treatment Effectiveness Assessment (TEA)) and changes in anxiety (using Generalized Anxiety Disorder scale (GAD-7)). Finally, data on the subjective experience of the treatment (using Ego Dissolution Inventory (EDI), Emotional Breakthrough Inventory (EBI) and Mystical Experience Questionnaire (MEQ30)) will be collected and used in a regression model with baseline measures to assess predictors of treatment response on measures of depression and AUD .
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Andreas W Blomkvist, M.D.
- Número de telefone: +47 41694637
- E-mail: andreas.wahl.blomkvist@unn.no
Estude backup de contato
- Nome: Ole K Grønli, Assoc Prof
- Número de telefone: +47 91713535
- E-mail: ole.k.gronli@unn.no
Locais de estudo
-
-
-
Moss, Noruega, 1535
- Ainda não está recrutando
- Department of Addiction Treatment, ØHT
-
Contato:
- Mina Piiksi Dahli, PhD, M.D.
- Número de telefone: +4769866300
- E-mail: mina.piiksi.dahli@so-hf.no
-
Investigador principal:
- Mina Piiksi Dahli, PhD, M.D.
-
Tromsø, Noruega
- Recrutamento
- Department of Addiction, University Hospital of North Norway
-
Contato:
- Andreas W Blomkvist, Senior consultant
- Número de telefone: +4741694637
- E-mail: andreas.wahl.blomkvist@unn.no
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Please contact the project team for a full and detailed list of inclusion/exclusion criteria
Inclusion Criteria:
- Currently abstinent from alcohol
- At least moderate depression without psychotic features
- Minimum Montgomery-Åsberg Depression Rating Scale (MADRS) of 20
- Alcohol dependence
- Admitted for inpatient addiction therapy at University Hospital of North Norway or Østfold Hospital Trust
Exclusion Criteria:
- Intoxicated or in significant withdrawal from alcohol or drug use
- Not able to give adequate informed consent
- Current or past history of schizophrenia, schizophreniform disorder, paranoid delusional disorder, schizoaffective disorder
- Current or historical diagnosis of schizophrenia in a first degree relative
- Cardiovascular conditions: recent stroke (< 1 year from informed consent), recent myocardial infarction (< 1 year from informed consent), uncontrolled hypertension (>150/100 mm Hg) or recent arrhythmia (< 1 year from informed consent; clinically significant arrhythmia requiring treatment at hospital)
- Liver (Child-Pughs Class C) or kidney (Creatinin clearance < 30 mL/min) failure
- Heart failure (the New York Heart Association Functional Classification (NYHA) class III or IV)
- Chronic respiratory failure (requiring long-term oxygen therapy (LTOT) and/or Global Initiative for Chronic Obstructive Lung Disease system (GOLD) stage 3 or higher)
- Previous anaphylactic reaction to ketamine or midazolam
- Illegal use of ketamine the last 6 months
- Pregnancy or breastfeeding
- Current or suspected increased intracranial pressure
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention group
Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks) |
Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes |
|
Comparador Ativo: Control group
Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks) |
Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Depression
Prazo: Within 3 days after final treatment session
|
Change from baseline using rater-blinded Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome) |
Within 3 days after final treatment session
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Alcohol craving tonic
Prazo: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
|
Penn Alcohol Craving Scale (PACS) (range 0-30; higher score indicate worse outcome) |
Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
|
|
Alcohol craving phasic
Prazo: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
|
Alcohol Craving Questionnaire - Short version (ACQ-short) (range 12-84; higher score indicate worse outcome) |
Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
|
|
Depression response/remission
Prazo: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
|
Rates of response (50% or more reduction in MADRS from baseline) and remission (9 points or less in MADRS) |
Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
|
|
Relapse risk
Prazo: From baseline until 6 months after baseline
|
Incidence of relapse in each group (defined as two or more consecutive heavy drinking days) |
From baseline until 6 months after baseline
|
|
Time until relapse
Prazo: From baseline until 3 and 6 months after baseline
|
Average time from final treatment session until relapse |
From baseline until 3 and 6 months after baseline
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Duration of antidepressant effect (blinded-rater assessed)
Prazo: From baseline until 6 months after baseline
|
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome) |
From baseline until 6 months after baseline
|
|
Duration of antidepressant effect (self-report)
Prazo: From baseline until 6 months after baseline
|
Change in the Beck Depression Inventory-II (BDI-II) (Range 0-63; higher score indicate worse outcome) |
From baseline until 6 months after baseline
|
|
Tolerability using the ketamine side effect tool (KSET)
Prazo: Up to 1 month
|
Physician-reported tolerability of each treatment session (good, moderate and poor) |
Up to 1 month
|
|
Tolerability using the ketamine side effect tool (KSET)
Prazo: Up to 1 month
|
Patient-reported tolerability of each treatment session (good, moderate and poor) |
Up to 1 month
|
|
Cambridge Neuropsychological Test Automated Battery (CANTAB): Stop Signal Task (SST); Spatial Working Memory (SWM) task; Intra-Extra Dimensional Shift (IED) task; Paired Associates Learning (PAL) task; Emotional Bias Task (EBT)
Prazo: Within 3 days after final treatment session
|
Assess within- and between-group changes in neurocognitive function from baseline to within three days from the final treatment session: SST (Range 0-1000; Lower score indicate better outcome); SWM (Range: 2-14; Lower score indicates better outcome); IED (Range: 0-402; Lower score indicates better outcome); PAL (Range: 0-70; Lower score indicates better outcome); EBT (Range: 0-15; Higher score indicates better outcome (more happy)) |
Within 3 days after final treatment session
|
|
Adverse reaction frequency
Prazo: Up to 6 months
|
Frequency of adverse reactions |
Up to 6 months
|
|
Adverse reaction severity
Prazo: Up to 6 months
|
Number of mild, moderate and severe adverse reactions |
Up to 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Ole K Grønli, Assoc Prof, University Hospital of North Norway
- Investigador principal: Andreas W Blomkvist, M.D., University Hospital of North Norway
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Sintomas Comportamentais
- Transtornos Relacionados a Substâncias
- Distúrbios induzidos quimicamente
- Distúrbios Relacionados ao Álcool
- Comportamento compulsivo
- Comportamento impulsivo
- Comportamento
- Alcoolismo
- Depressão
- Comportamental, Viciante
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Hidrocarbonetos
- Ciclohexanos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Benzazepínicos
- Benzodiazepínicos
- Midazolam
- Cetamina
Outros números de identificação do estudo
- 2022/484848(REK)
- 2023-506052-24 (Número EudraCT)
- U1111-1293-2654 (Outro identificador: WHO UTN)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be shared with external researchers because the participant information and consent form limits research access to those formally affiliated with the KeDA trial.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .